FDA Approves Lipfendra, the First Oral PCSK9 Inhibitor for High Cholesterol
Merck’s once-daily pill offers a needle-free alternative to injectable PCSK9 inhibitors for lowering LDL cholesterol
For years, PCSK9 inhibitors have been among the most effective medicines for lowering low-density lipoprotein cholesterol (LDL-C), often referred to as “bad cholesterol.” However, these therapies have required injections every two weeks or monthly, limiting their acceptance among some patients.
That could soon change.
The U.S. Food and Drug Administration (FDA) has approved Lipfendra® (enlicitide), the first oral PCSK9 inhibitor, marking a significant milestone in cardiovascular medicine. Developed by Merck Sharp & Dohme, Lipfendra is a once-daily tablet approved for adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH), to be used alongside diet, exercise, and maximally tolerated statin therapy.
The approval introduces the first needle-free therapy that directly targets the PCSK9 pathway—one of the most important advances in cholesterol management over the past two decades.
Why Lowering LDL Cholesterol Matters
High LDL cholesterol is one of the strongest modifiable risk factors for cardiovascular disease, including heart attacks and strokes—the leading causes of death worldwide.
Excess LDL cholesterol gradually accumulates inside artery walls, forming fatty plaques that narrow blood vessels. If these plaques rupture, they can trigger blood clots that block blood flow to the heart or brain.
Because high cholesterol usually causes no symptoms, millions of people remain unaware they are at risk until a blood test reveals elevated LDL levels.
What Is PCSK9?
PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) is a protein produced mainly by the liver that regulates the number of LDL receptors on liver cells.
Normally, LDL receptors remove LDL cholesterol from the bloodstream. However, PCSK9 binds to these receptors and targets them for destruction, reducing the liver’s ability to clear cholesterol.
Blocking PCSK9 allows more LDL receptors to remain on liver cells, dramatically increasing cholesterol removal from the blood.
Until now, all approved PCSK9 inhibitors—including monoclonal antibodies—have required injections.
Lipfendra changes that by delivering PCSK9 inhibition in the form of a daily oral tablet.
Clinical Trial Results
The FDA approval was based on two large Phase 3 randomized, double-blind, placebo-controlled clinical trials involving 3,207 adults already receiving maximally tolerated statin therapy.
Patients with Established or High Cardiovascular Risk
The first study enrolled adults with atherosclerotic cardiovascular disease (ASCVD) or individuals at high cardiovascular risk.
- Average baseline LDL-C: 96 mg/dL
- LDL cholesterol reduction after 24 weeks:
- Lipfendra: 56% reduction
- Placebo: significantly less reduction
Patients with Familial Hypercholesterolemia
The second study focused on patients with heterozygous familial hypercholesterolemia (HeFH), an inherited disorder that causes lifelong elevated cholesterol levels.
- Average baseline LDL-C: 119 mg/dL
- LDL cholesterol reduction after 24 weeks:
- Lipfendra: 59% reduction
- Placebo: significantly less reduction
These reductions are comparable to those achieved with currently available injectable PCSK9 inhibitors.
Safety Profile
Lipfendra demonstrated a favorable safety profile in clinical trials.
Among patients with HeFH, the most commonly reported adverse effects occurring more frequently than placebo were:
- Diarrhea
- Dizziness
Rates of treatment discontinuation due to adverse events were similar between Lipfendra and placebo groups, suggesting good overall tolerability.
Why This Approval Is Important
The introduction of an oral PCSK9 inhibitor could significantly expand access to one of the most effective cholesterol-lowering strategies.
Many patients who qualify for injectable PCSK9 inhibitors either delay treatment or discontinue therapy because of concerns about injections, cost, or convenience.
A once-daily tablet may improve adherence while simplifying long-term cholesterol management.
The approval also broadens the therapeutic options available after statins and ezetimibe, particularly for patients who remain at high cardiovascular risk despite standard therapy.
Not a Replacement for Healthy Living
Although Lipfendra is highly effective, it is not intended to replace lifestyle modification.
The FDA recommends that the medication be used alongside a heart-healthy diet, regular physical activity, and maximally tolerated statin therapy.
For many patients, combination therapy remains the most effective approach for reducing cardiovascular risk.
A New Chapter in Cholesterol Management
The approval of Lipfendra represents more than just another cholesterol-lowering drug. It marks the first time one of the most powerful lipid-lowering mechanisms has become available in a convenient oral formulation.
As cardiovascular disease continues to impose a major global health burden, therapies that combine efficacy with ease of use could help more patients achieve recommended LDL cholesterol targets and potentially reduce the risk of heart attacks and strokes.
Whether Lipfendra ultimately transforms routine clinical practice will depend on long-term cardiovascular outcome data, pricing, accessibility, and physician adoption. Nevertheless, its approval signals an important new direction in lipid-lowering therapy.
Key Highlights
- First oral PCSK9 inhibitor approved by the FDA
- Brand name: Lipfendra®
- Generic name: Enlicitide
- Developer: Merck Sharp & Dohme
- Indication: Adults with hypercholesterolemia and heterozygous familial hypercholesterolemia (HeFH)
- Administration: Once-daily oral tablet
- LDL-C reduction: Up to 59% in Phase 3 trials
- Used with: Diet, exercise, and maximally tolerated statin therapy
